Complix

Complix is a biopharmaceutical company dedicated to the discovery and development of Alphabodies™, a new class of biopharmaceuticals that offer significant advantages over existing protein therapies. Alphabodies™ bind to a wide range of disease targets with high affinity, making them particularly suitable for addressing certain targets that are difficult to reach with antibodies or other types of protein scaffolds. Due to their unique stability and versatility, Alphabodies™ can be administered through alternative non-injectable delivery routes, unlike most therapeutic proteins.